Mizuho Securities analyst Mara Goldstein maintained a Buy rating on IN8bio (INAB – Research Report) yesterday and set a price target of $12.00. The company’s shares closed yesterday at $1.15.
Goldstein covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Arcus Biosciences, and Merck & Company. According to TipRanks, Goldstein has an average return of -4.6% and a 33.86% success rate on recommended stocks.
Currently, the analyst consensus on IN8bio is a Strong Buy with an average price target of $11.33.
See the top stocks recommended by analysts >>
INAB market cap is currently $35.7M and has a P/E ratio of -0.89.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.
Read More on INAB:
